Kinetic and structural studies of Mycobacterium tuberculosis dihydroorotate dehydrogenase reveal new insights into class 2 DHODH inhibition

Author(s)

Teixeira, Olivia ; Martins, Ingrid Bernardes Santana ; Froes, Thamires Quadros ; de Araujo, Alexandre Suman ; Nonato, Maria Cristina

• Document type: Journal article
• Source: BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS; v. 1867, n. 7, p. 10-pg., 2023-07-01.

Abstract

Tuberculosis (TB) is a leading cause of death worldwide. TB represents a serious public health threat, and it is characterized by high transmission rates, prevalence in impoverished regions, and high co-infection rates with HIV. Moreover, the serious side effects of long-term treatment that decrease patient adherence, and the emergence of multi-resistant strains of Mycobacterium tuberculosis, the causing agent of TBs, pose several challenges for its eradication. The search for a new TB treatment is necessary and urgent. Dihydroorotate dehydrogenase (DHODH) is responsible for the stereospecific oxidation of (S)-dihydroorotate (DHO) to orotate during the fourth and only redox step of the de novo pyrimidine nucleotide biosynthetic pathway. DHODH has been considered an attractive target against infectious diseases. As a first step towards exploiting DHODH as a drug target against TB, we performed a full kinetic characterization of both bacterial MtDHODH and its human ortholog (HsDHDOH) using both substrates coenzyme Q0 (Q0) and vitamin K3 (K3). MtDHODH follows a ping-pong mechanism of catalysis and shares similar catalytic parameters with the human enzyme. Serendipitously, Q0 was found to inhibit MtDHODH (KI (Q0) = 138 & PLUSMN; 31 & mu;M). To the best of our knowledge, Q0 is the first non-orotate like dihydroorotate-competitive inhibitor for class 2 DHODHs ever described. Molecular dynamics simulations along with in silico solvent mapping allowed us to successfully probe protein flexibility and correlate it with the druggability of binding sites. Together, our results provide the starting point for the design of a new generation of potent and selective inhibitors against MtDHODH. (AU)

• FAPESP's process: 19/25532-1 - Hot spots identification and molecular fragment screening as innovative approaches to development Leishmania major diidroorotate dehydrogenase inhibitors
• Grantee: Thamires Quadros Froes
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 20/16316-0 - Search for potent and selective inhibitors to Mycobacterium tuberculosis dihydroorotate dehydrogenase (MtDHODH)
• Grantee: Olívia Teixeira
• Support Opportunities: Scholarships in Brazil - Master